Patients with castration-resistant prostate cancer (CRPC), who progress after docetaxel therapy, had until very recently, only a few\r\ntherapeutic options. Recent advances in this field brought about new perspectives in the treatment of this disease.Molecular, basic,\r\nand translational research has given us a better understanding on the mechanisms of CRPC. This great investment has turned\r\ninto a more rational approach to the development of new drugs. Some of the new treatments are already available to our patients\r\noutside clinical trials and may include inhibitors of androgen biosynthesis; new chemotherapy agents; bone-targeted therapy; and\r\nimmunotherapy. This paper aims to review the mechanisms of prostate cancer resistance, possible therapeutic targets, as well as\r\nnew options to treat CRPC.
Loading....